The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include elevated hepatic or muscular enzymes, neurological symptoms, and muscular symptoms collectively referred to as statin-associated muscle symptoms (SAMS).1 SAMS seems to occur less frequently in randomized control trials than in observational studies. These results suggest that … [Read more...] about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
Imaging
Top 10 Highlights of AHA 2020 Congress
The American Heart Association (AHA) 2020 congress took place virtually this year, from November 13 to 17, 2020. Here is our curated list of the top scientific sessions from AHA 2020. SOLOIST-WHF trial1: Sotagliflozin superior to placebo in preventing deaths and hospitalizations in patients with type 2 diabetes and worsening heart failure. This multicenter, double-blind … [Read more...] about Top 10 Highlights of AHA 2020 Congress
Top 10 highlights of TCT 2020 Congress
This year the Transcatheter Cardiovascular Therapeutics (TCT, TCT Connect 2020) congress was held as a virtual event October14 - 18, 2020, broadcasting live case-based transmissions from around the world, late-breaking clinical trials and virtual training in interventional cardiovascular medicine. Here is our curated list of the top 10 highlights of the symposium (TCT … [Read more...] about Top 10 highlights of TCT 2020 Congress
Top 10 highlights of ESC Congress 2020
This year’s European Society of Cardiology (ESC) congress was the first ever to be held entirely digitally, due to the COVID-19 pandemic. Approximately 116,000 healthcare providers from 211 countries participated, and there were many illuminating presentations shared to help guide the management of cardiovascular disease. Here are our top 10 highlights listed by … [Read more...] about Top 10 highlights of ESC Congress 2020
iMODERN: When to treat non-culprit lesions in STEMI
The iMODERN trial (“iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction.”) trial is an ongoing multinational study. This study will provide important knowledge on the best practice for the assessment and treatment of multi-vessel disease involving ST-segment elevation myocardial infarction (STEMI) patients. We … [Read more...] about iMODERN: When to treat non-culprit lesions in STEMI